|Dr. Adam R. Craig||Pres, CEO, Interim Chief Medical Officer & Director||1.03M||N/A||1966|
|Mr. David H. Kirske||Exec. VP, CFO & Sec.||511.74k||N/A||1954|
|Mr. Bruce J. Seeley||Exec. VP & COO||598k||N/A||1964|
|Mr. Ed Bell||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Jim Fong||Sr. VP of Global Operations||N/A||N/A||N/A|
|Mr. Bruce K. Bennett Jr.||Sr. VP Global Pharmaceutical Operations||N/A||N/A||1952|
|Mr. John Volpone||Sr. VP of Strategic Operations||N/A||N/A||N/A|
|Dr. Jennifer A. Smith||Sr. VP of Biometrics||N/A||N/A||N/A|
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
CTI BioPharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.